SREBF2 and Wilson disease: Liver‐specific knockout of Srebf2 in Ldlr+/+ mice by Alb‐Cre resulted in substantially reduced plasma TG and TC levels, which is likely attributed to diminished hepatic VLDL secretion rate as hepatic LDLR protein levels are not impaired.[15] To measure hepatic VLDL secretion, poloxamer‐407, an effective inhibitor of peripheral lipoprotein lipase, was administered in mice at 3 weeks (chow) or 8 weeks (3 weeks of WD) post AAV injection, and plasma TG and TC levels were monitored for 2h.